Chronic use of Renin-Angiotensin-Aldosterone-System blockers and mortality in COVID-19: a multicenter prospective cohort and literature review.

Date publication

avril 2021

Journal

Fundamental & clinical pharmacology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick

Tous les auteurs :
Gault N, Esposito-Farese M, Revest M, Inamo J, Cabie A, Polard É, Hulot JS, Ghosn J, Chirouze C, Deconinck L, Diehl JL, Poissy J, Epaulard O, Lefèvre B, Piroth L, de Montmollin E, Oziol E, Etienne M, Laouenan C, Rossignol P, Costagliola D, Vidal-Petiot E,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33876439

Résumé

The role of renin-angiotensin-aldosterone system (RAAS) blockers on the course of coronavirus disease 2019 (COVID-19) is debated. We assessed the association between chronic use of RAAS blockers and mortality among inpatients with COVID-19, and explored reasons for discrepancies in the literature.

Mots clés

COVID-19, RAAS blockers, angiotensin antagonists, hypertension, mortality, propensity score

Référence

Fundam Clin Pharmacol. 2021 Apr 20;: